Radiopharmaceuticals in PET Imaging Market Size is predicted to grow with a 12.7% CAGR during the forecast period for 2025-2034.
In medical imaging, Positron Emission Tomography (PET) has emerged as a key technique for the diagnosis and treatment of a number of illnesses, most notably cancer, neurological disorders, and cardiovascular ailments. Radiopharmaceuticals, which are radioactive substances used as tracers to see biological processes in vivo, are essential to the success of PET imaging. The market for these goods is expanding quickly because of developments in PET technology and the creation of novel radiopharmaceuticals.
The growing need for early illness detection, especially for cancer and neurological disorders, is fueling the global market for radiopharmaceuticals in PET imaging. Radiopharmaceuticals aid in tumour detection, therapy effectiveness monitoring, and organ metabolic function evaluation. The market for radiopharmaceuticals in PET imaging is poised for substantial development due to ongoing technical advancements, rising healthcare spending, and growing precision medicine applications.
In addition, to visualize brain activity and identify neurological conditions, including epilepsy, Parkinson's disease, and Alzheimer's disease, radiopharmaceuticals are crucial. The radiopharmaceuticals in the PET imaging market is expanding because of the growing need for neurological PET imaging and the ageing population.
Competitive Landscape
Some Major Key Players In The Radiopharmaceuticals in PET Imaging Market:
• Siemens Healthineers AG
• GE Healthcare
• Eli Lilly and Company
• Telix Pharmaceuticals
• Bracco Imaging S.p.A.
• SOFIE Biosciences
• Lantheus Holdings, Inc.
• Curium
• Advanced Accelerator Applications (Novartis)
• Other Market Players
Market Segmentation:
The Radiopharmaceuticals in PET Imaging market is segmented based on Radioisotope Type, Application, and End-user. Based on radioisotope type, the market is segmented into F-18 FDG, F-18 Fiorbetapir, F-18 Fiobetaben, F-18 Sodium Fluoride, and Others. The applicaiton segment comprises Oncology (Lung Cancer, Breast Cancer, Others), Cardiology, Neurology (Dementia, Parkinson's Disease, Others), and Others. By end-user, the segmentation includes Hospitals and Clinics, Medical Imaging Centers, and Other End-users.
Based On The Radioisotope Type, The F-18 Sodium Fluoride Segment Is Accounted As A Major Contributor To The Radiopharmaceuticals In PET Imaging Market
The F-18 Sodium Fluoride category is expected to hold a major global market share in 2021 driven by its growing use in cancer and bone scanning applications. When compared to traditional technetium-based bone scans, F-18 NaF is a highly effective PET radiotracer for detecting bone metastases, providing better imaging quality and faster uptake. The market for F-18 NaF has increased as a result of the increased demand for more accurate diagnostic tools brought on by the rising incidence of cancer, especially breast and prostate cancer. Developments in technology and growing provider awareness of the advantages of early and precise bone disease detection are also accelerating PET/CT use.
Oncology Segment To Witness Growth At A Rapid Rate
The increasing global existance of cancer and the growing need for accurate and early tumour identification are driving the expansion of the oncology sector in the market for radiopharmaceuticals for PET imaging. F-18 Fluorodeoxyglucose (FDG) and F-18 Sodium Fluoride (NaF) are two examples of PET radiopharmaceuticals that are essential for cancer diagnosis, staging, treatment planning, and therapy response monitoring. Technological developments have significantly improved the precision and therapeutic usefulness of PET imaging in oncology in hybrid imaging systems.
In The Region, The North American Radiopharmaceuticals In PET Imaging Market Holds A Significant Revenue Share
The North American Radiopharmaceuticals in PET Imaging market is expected to register the highest market share in revenue in the near future. In North America, cancer and neurological conditions, including Parkinson's, Alzheimer's, and other dementias, are becoming more common. In neurology and cancer, PET imaging is an essential tool, especially for continuing monitoring, therapy planning, and early discovery. This tendency is anticipated to continue as the population ages, increasing the need for radiopharmaceuticals in PET. In addition, Europe is projected to grow rapidly in the global Radiopharmaceuticals in PET Imaging market.
Radiopharmaceuticals in PET Imaging Market Report Scope:
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 12.7% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2024-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Radioisotope Type, Application, and End-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia |
|
Competitive Landscape |
Siemens Healthineers AG, GE Healthcare, Eli Lilly and Company, Telix Pharmaceuticals, Bracco Imaging S.p.A., SOFIE Biosciences, Lantheus Holdings, Inc., Curium, amd Advanced Accelerator Applications (Novartis). |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
